https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-05-30 / Physiol Res 2008;57(2):289-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-05-30 / Physiol Res 2008;57(2):289-982007-05-30 00:00:002007-05-30 00:00:00Dendritic cells and T lymphocyte interactions in patients with lymphoid malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-04-04 / Br. J. Haematol. 2007 May;137(4):297-306
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-04-04 / Br. J. Haematol. 2007 May;137(4):297-3062007-04-04 00:00:002019-02-15 08:37:28Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Expert Rev Anticancer Ther 2007 Mar;7(3):275-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Expert Rev Anticancer Ther 2007 Mar;7(3):275-832007-03-01 00:00:002019-02-15 08:37:33Dendritic cell vaccines for leukemia patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-10-01 / Curr Drug Targets 2006 Oct;7(10):1371-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-10-01 / Curr Drug Targets 2006 Oct;7(10):1371-42006-10-01 00:00:002019-02-15 08:51:26Current status of immunotherapy in B cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-01 / Leuk. Lymphoma 2006 Apr;47(4):675-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-01 / Leuk. Lymphoma 2006 Apr;47(4):675-822006-04-01 00:00:002006-04-01 00:00:00Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-03-09 / Leuk. Res. 2006 Jul;30(7):785-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-03-09 / Leuk. Res. 2006 Jul;30(7):785-942006-03-09 00:00:002019-02-15 08:37:29Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-03 / J. Leukoc. Biol. 2006 Apr;79(4):747-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-03 / J. Leukoc. Biol. 2006 Apr;79(4):747-562006-02-03 00:00:002019-02-15 08:37:30Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Leuk. Lymphoma 2006 Feb;47(2):297-306
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Leuk. Lymphoma 2006 Feb;47(2):297-3062006-02-01 00:00:002019-02-15 08:37:31Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(4):318-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(4):318-262006-01-01 00:00:002019-02-15 08:45:56Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Pathology 2005 Dec;37(6):534-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Pathology 2005 Dec;37(6):534-502005-12-01 00:00:002019-02-15 08:51:27Vaccine strategies to treat lymphoproliferative disorders
